[HTML][HTML] Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
A Drilon, DR Camidge, JJ Lin, SW Kim… - … England Journal of …, 2024 - Mass Medical Soc
Background The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved
for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have …
for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have …
Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised …
E Baudin, B Goichot, A Berruti, J Hadoux, S Moalla… - The Lancet, 2024 - thelancet.com
Background No randomised controlled trial has ever been done in patients with metastatic
phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested …
phaeochromocytomas and paragangliomas. Preclinical and first clinical evidence suggested …
Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series
MJ Hjermstad, G Jakobsen, J Arends… - Journal of Cachexia …, 2024 - Wiley Online Library
The use of patient‐reported outcomes (PROMs) of quality of life (QOL) is common in
cachexia trials. Patients' self‐report on health, functioning, wellbeing, and perceptions of …
cachexia trials. Patients' self‐report on health, functioning, wellbeing, and perceptions of …
A Systematic Review of Health-Related Quality of Life in Women with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
SM Khoirunnisa, FDA Suryanegara, LA de Jong… - PharmacoEconomics …, 2024 - Springer
Background Many trials of human epidermal growth factor receptor 2 (HER2)-positive
metastatic breast cancer treatment with trastuzumab have provided evidence of improved …
metastatic breast cancer treatment with trastuzumab have provided evidence of improved …
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a …
Background Anti-PD-1 therapy and chemotherapy is a recommended first-line treatment for
recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains …
recurrent or metastatic nasopharyngeal carcinoma, but the role of PD-1 blockade remains …
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage …
Background At the first interim analysis of the KEYNOTE-671 trial, adding perioperative
pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in …
pembrolizumab to neoadjuvant chemotherapy significantly improved event-free survival in …
Patient-reported outcomes in patients with Advanced Urothelial Cancer who are Ineligible for Cisplatin and treated with First-Line Enfortumab Vedotin alone or with …
MI Milowsky, PH O'Donnell, CJ Hoimes… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE Locally advanced/metastatic urothelial cancer (la/mUC) affects patients' quality of
life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) …
life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) …
The impact of outpatient versus inpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised …
P Sivakumar, DB Fitzgerald, H Ip, D Rao… - European …, 2024 - Eur Respiratory Soc
Background The principal aim of malignant pleural effusion (MPE) management is to
improve health-related quality of life (HRQoL) and symptoms. Methods In this open-label …
improve health-related quality of life (HRQoL) and symptoms. Methods In this open-label …
Pralsetinib in patients with advanced/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study
V Subbiah, MI Hu, AS Mansfield, MH Taylor, M Schuler… - Thyroid, 2024 - liebertpub.com
Background: Rearranged during transfection (RET) alterations are targetable oncogenic
drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study …
drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study …
Five-year follow-up of health-related quality of life in differentiated thyroid cancer patients treated with total thyroidectomy and radioiodine in Sweden: a nationwide …
J Winter, E Axelsson, L Björkhem-Bergman… - Thyroid, 2024 - liebertpub.com
Background: Despite a good prognosis, survivors of differentiated thyroid cancer (DTC) may
have reduced health-related quality of life (HRQOL) many years after treatment, and it is …
have reduced health-related quality of life (HRQOL) many years after treatment, and it is …